- Conditions
- Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer, Colorectal Cancer
- Interventions
- SON-DP
- Drug
- Lead sponsor
- Qurgen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 5
- States / cities
- Gilbert, Arizona • Detroit, Michigan • Huntersville, North Carolina + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1033–1056
of 7,243
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Symptomatic Hypertrophic Cardiomyopathy (HCM)
- Interventions
- Aficamten (5 - 20 mg)
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 43 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Alisertib, Placebo, Paclitaxel
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 21
- States / cities
- Los Angeles, California • Sacramento, California • New Haven, Connecticut + 18 more
- Conditions
- Gallbladder Carcinoma, Metastatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Cholangiocarcinoma
- Interventions
- Atezolizumab, Biopsy, Biospecimen Collection, Cobimetinib, Computed Tomography, Magnetic Resonance Imaging
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 41
- States / cities
- Duarte, California • Sacramento, California • South Pasadena, California + 31 more
- Conditions
- Type 2 Diabetes
- Interventions
- Not listed
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Cancer
- Interventions
- MEDI-547
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Detroit, Michigan
- Conditions
- Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma
- Interventions
- Cisplatin, IMRT 6 weeks, IMRT 5 weeks
- Drug · Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 207
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 168 more
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Pembrolizumab, MK-4830, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab, Favezelimab/Pembrolizumab
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 11
- States / cities
- San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 7 more
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- TAK-188
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 15
- States / cities
- Santa Monica, California • New Haven, Connecticut • Orlando, Florida + 12 more
- Conditions
- Kidney Cancer
- Interventions
- aldesleukin, bevacizumab
- Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Maywood, Illinois • Indianapolis, Indiana + 8 more
- Conditions
- Advanced Solid Tumors With MAPK Pathway Mutations
- Interventions
- D3S-002, D3S-001
- Drug
- Lead sponsor
- D3 Bio (Wuxi) Co., Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • New York, New York • Nashville, Tennessee + 1 more
- Conditions
- Cardiovascular Disease
- Interventions
- bococizumab (PF-04950615), Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 518
- States / cities
- Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 328 more
- Conditions
- Prostate Cancer
- Interventions
- bicalutamide, radiation therapy, placebo
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- Male only
- Enrollment
- 840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2022
- U.S. locations
- 221
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 168 more
- Conditions
- Acute Kidney Injury
- Interventions
- Auxora, Placebo
- Drug
- Lead sponsor
- CalciMedica, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 28 more
- Conditions
- Chronic Heart Failure With Reduced Systolic Function
- Interventions
- Dapagliflozin, Dapagliflozin matching placebo
- Drug
- Lead sponsor
- Saint Luke's Health System
- Other
- Eligibility
- 19 Years to 119 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 25
- States / cities
- Fairhope, Alabama • Los Angeles, California • Jacksonville, Florida + 20 more
- Conditions
- Leukemia
- Interventions
- filgrastim, cladribine, idarubicin
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2007
- U.S. locations
- 206
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
- Conditions
- Breast Neoplasms
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 30 Years to 70 Years · Female only
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- HRAS Gene Mutation, HNSCC
- Interventions
- Tipifarnib, HRAS Detection Assay
- Drug · Device
- Lead sponsor
- Kura Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 29
- States / cities
- Los Angeles, California • San Francisco, California • Whittier, California + 23 more
- Conditions
- Myeloid Malignancies
- Interventions
- Magrolimab, Azacitidine, Venetoclax, Mitoxantrone, Etoposide, Cytarabine, CC-486
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 13 more
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Cilofexor, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 419 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 82
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Coronado, California + 65 more
- Conditions
- Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
- Interventions
- MODI Algorithm
- Device
- Lead sponsor
- DreaMed Diabetes
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 6
- States / cities
- Baltimore, Maryland • Detroit, Michigan • Albany, New York + 3 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Glatiramer acetate
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2018
- U.S. locations
- 11
- States / cities
- Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 7 more
- Conditions
- HIV/AIDS, HIV Infections
- Interventions
- We Test, IHTC
- Behavioral
- Lead sponsor
- Florida State University
- Other
- Eligibility
- 15 Years to 24 Years · Male only
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • New York, New York
- Conditions
- Advanced Malignancies
- Interventions
- MGCD265
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Houston, Texas